Cilnidipine is a Small Molecule owned by Ajinomoto Co, and is involved in 2 clinical trials, which were completed.
Cilnidipine acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, Cilnidipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. It also acts on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. The blockade of N-type Ca2+ channels effectively suppresses neurohumoral regulation in the cardiovascular system, including sympathetic nervous system and renin-angiotensin-aldosterone system. Hence cilnidipine is favorable for various types of complication of hypertension.
The revenue for Cilnidipine is expected to reach a total of $97m through 2028. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cilnidipine NPV Report.
Cilnidipine (Atelec) is a dihydropyridine derivative acts as anti-hypertensive agent. It is formulated as film coated tablets for oral route of administration. Atelec is indicated for the treatment of hypertension.
Mochida Pharmaceutical Overview
Mochida Pharmaceutical (Mochida) develops, manufactures, and markets pharmaceutical and healthcare products including generics, specialty pharmaceuticals, and biosimilar products. The company’s products are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, pulmonary arterial hypertension, endometriosis, adenomyosis, thrombosis, acute pancreatitis, depression and depressive symptoms, chronic pain, cancer, chronic constipation, ulcerative colitis, gout and hyperuricemia, anticoagulant, antimycotic, and others. Its products under development are intended for the treatment of ulcerative colitis, insomnia, hyperlipidemia, articular cartilage lesion, and others. The company also offers contract manufacturing of pharmaceuticals. It operates state of art manufacturing facilities in Japan involved in technology transfers and the development of new drugs. Mochida is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY110,179 million for the fiscal year ended March 2022 (FY2022), an increase of 7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.4% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 8.3% in FY2021. The company reported revenues of JPY25,508 million for the second quarter ended September 2022, a decrease of 7.9% over the previous quarter.
Quick View – Cilnidipine
|Highest Development Stage|